Cargando…
Monoclonal antibodies and Fc-fusion protein biologic medicines: A multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020
BACKGROUND: Monoclonal antibody (mAb) and Fc-fusion protein (FcP) are highly effective therapeutic biologics. We aimed to analyse consumption and expenditure trends in 14 Asia-Pacific countries/regions (APAC) and three benchmark countries (the UK, Canada, and the US). METHODS: We analysed 440 mAb an...
Autores principales: | Tong, Xinning, Li, Xue, Pratt, Nicole L., Hillen, Jodie B., Stanford, Tyman, Ward, Michael, Roughead, Elizabeth E., Lai, Edward Chia-Cheng, Shin, Ju-Young, Cheng, Franco W.T., Peng, Kuan, Lau, Chak Sing, Leung, Wai Keung, Wong, Ian C.K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249810/ https://www.ncbi.nlm.nih.gov/pubmed/35789824 http://dx.doi.org/10.1016/j.lanwpc.2022.100506 |
Ejemplares similares
-
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
por: Peng, Kuan, et al.
Publicado: (2023) -
Rituximab and Pyoderma Gangrenosum: An Investigation of Disproportionality Using a Systems Biology-Informed Approach in the FAERS Database
por: Hillen, Jodie Belinda, et al.
Publicado: (2022) -
Multinational survey on the preferred approach to management of Barrett’s esophagus in the Asia-Pacific region
por: Kew, Guan Sen, et al.
Publicado: (2021) -
Asia Pacific Allergy: Asia Pacific and beyond
por: Chang, Yoon-Seok
Publicado: (2022) -
Asia Pacific
Publicado: (2020)